Products

Our factory provides China Iminazole, Pyridine, Heterocyclics, Iguratimod, Apremilast, Bromhexine HCl, ect. Everyone knows us for our excellent service, fair prices, and high caliber products. You are welcome to place an order.
View as  
 
CAS 169590-42-5

CAS 169590-42-5

CAS 169590-42-5 is for nonsteroidal anti-inflammatory drug, for osteoarthritis drug, rheumatoid arthritis drug, juvenile rheumatoid arthritis drug.

Read MoreSend Inquiry
169590-42-5

169590-42-5

169590-42-5 is for nonsteroidal anti-inflammatory drug, for osteoarthritis drug, rheumatoid arthritis drug, juvenile rheumatoid arthritis drug.

Read MoreSend Inquiry
Celecoxib API

Celecoxib API

Celecoxib API is for nonsteroidal anti-inflammatory drug, for osteoarthritis drug, rheumatoid arthritis drug, juvenile rheumatoid arthritis drug.

Read MoreSend Inquiry
(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-b-oxo-1-piperidinepropanenitrile: 2-Hydroxy-1,2,3-propanetricarboxylate

(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-b-oxo-1-piperidinepropanenitrile: 2-Hydroxy-1,2,3-propanetricarboxylate

(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-b-oxo-1-piperidinepropanenitrile: 2-Hydroxy-1,2,3-propanetricarboxylate is for rheumatoid arthritis drug, psoriatic arthritis drug, ankylosing spondylitis drug, polyarticular course juvenile idiopathic arthritis drug, ulcerative colitis drug.

Read MoreSend Inquiry
CAS NO.540737-29-9

CAS NO.540737-29-9

CAS NO.540737-29-9 is for rheumatoid arthritis drug, psoriatic arthritis drug, ankylosing spondylitis drug, polyarticular course juvenile idiopathic arthritis drug, ulcerative colitis drug.

Read MoreSend Inquiry
CAS 540737-29-9

CAS 540737-29-9

CAS 540737-29-9 is for rheumatoid arthritis drug, psoriatic arthritis drug, ankylosing spondylitis drug, polyarticular course juvenile idiopathic arthritis drug, ulcerative colitis drug.

Read MoreSend Inquiry
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept